Fofie Christian Kuete, Granja-Vazquez Rafael, Truong Vincent, Walsh Patrick, Price Theodore, Biswas Swati, Dussor Gregory, Pancrazio Joseph, Kolber Benedict
Department of Neuroscience and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, TX 75080, USA.
Anatomic Incorporated, Minneapolis, MN 55413, USA.
Cell Rep Methods. 2025 May 19;5(5):101051. doi: 10.1016/j.crmeth.2025.101051. Epub 2025 May 13.
Chronic pain is a global health issue, yet effective treatments remain limited due to poor preclinical-to-human translation. To address this, we developed a high-content screening (HCS) platform using hiPSC-derived nociceptors to identify analgesics targeting the peripheral nervous system. These cells, cultured on multi-well microelectrode arrays, achieved nearly 100% active electrodes by week 2, maintaining stable activity for at least 2 weeks. After 28 days, we assessed drug effects on neuronal activity, achieving strong assay performance (robust Z' > 0.5). Pharmacological tests confirmed responses to key analgesic targets, including ion channels (Nav, Cav, Kv, and TRPV1), neurotransmitter receptors (AMPAR and GABA-R), and kinase inhibitors (tyrosine and JAK1/2). Transcriptomic analysis validated target expression, though levels differed from primary human DRG cells. The platform was used to screen over 700 natural compounds, demonstrating its potential for analgesic discovery. This HCS platform facilitates the rapid discovery of uncharacterized analgesics, reducing preclinical-to-human translation failure.
慢性疼痛是一个全球性的健康问题,但由于临床前研究成果向人体应用的转化效果不佳,有效的治疗方法仍然有限。为了解决这一问题,我们开发了一个高内涵筛选(HCS)平台,利用人诱导多能干细胞(hiPSC)衍生的伤害感受器来识别针对外周神经系统的镇痛药。这些细胞培养在多孔微电极阵列上,到第2周时活性电极的比例接近100%,并至少保持2周的稳定活性。28天后,我们评估了药物对神经元活性的影响,获得了较强的检测性能(稳健的Z' > 0.5)。药理学测试证实了对关键镇痛靶点的反应,包括离子通道(Nav、Cav、Kv和TRPV1)、神经递质受体(AMPAR和GABA-R)以及激酶抑制剂(酪氨酸和JAK1/2)。转录组分析验证了靶点的表达,尽管其水平与原代人背根神经节(DRG)细胞不同。该平台用于筛选700多种天然化合物,证明了其在镇痛药发现方面的潜力。这个HCS平台有助于快速发现未被表征的镇痛药,减少临床前研究成果向人体应用转化的失败。